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ABSTRACT
Introduction: Sickle cell disease (SCD) is highly
prevalent in Africa. Considered as a public health
problem, it is associated with high morbidity and
mortality. Neurological complications of SCD can cause
significant disability with important socioeconomic and
psychological impact on the patients and their families,
and can even lead to death if not properly managed.
There are important knowledge gaps regarding the
burden of neurological complications of SCD in African
populations. We propose to conduct the first
systematic review to summarise the epidemiological
data available on neurological complications of SCD in
Africa.
Methods and analysis: We will search PubMed,
MEDLINE, EMBASE and the African Index Medicus
from 1 January 1950 to 31 May 2016 for studies of
neurological complications of SCD in Africa. After
study selection, full-text paper acquisition, data
extraction and synthesis, we will assess all studies for
quality, risk of bias and heterogeneity. Appropriate
methods of meta-analysis will be used to pool
prevalence estimates from studies with similar features,
globally and in major subgroups. This protocol
complies with the 2015 Preferred Reporting Items for
Systematic reviews and Meta-Analysis protocols
(PRISMA-P) guidelines.
Ethics and dissemination: The proposed study will
use published data. Therefore, there is no requirement
for ethical approval. This review is expected to provide
relevant data to help quantify the burden of
neurological complications of SCD in African
populations, inform policymakers and identify further
research topics. The final report of the systematic
review will be published in a peer-reviewed journal and
presented at conferences.
Review registration number: CRD42016039574.
INTRODUCTION
Rationale
Sickle cell disease (SCD) is a well-known
genetic haematological disorder with variable
severity.1 It is characterised by the presence
of a pathological haemoglobin S that differs
from the normal one by the presence of the
amino acid Valine at position 6 of the
β-globin subunit rather than glutamic acid
(Glu6Val mutation). Haemoglobin S is
poorly soluble when deoxygenated and its
precipitation in red blood cells is the primum
movens of all the acute manifestations and
long-term complications of SCD.2
SCD affects millions of people worldwide.3
It is associated with severe complications
that have a negative impact on their quality
of life and survival.3 4 The incidence and the
prevalence of SCD in Africa have kept
increasing over the past decades. It is esti-
mated that 240 000 children are born with
SCD annually in sub-Saharan Africa (SSA)
and 50–80% of these children die before the
age of 5 years.5–7 The prevalence is highly
variable across Africa. It is as high as 45% in
Uganda,8 20–30% in Cameroon, Republic of
Congo, Gabon, Ghana and Nigeria,9–12 1–2%
in Northern Africa and <1% in southern
Africa.8 SCD remains a major public health
challenge in African countries because of
the lack of national health coverage systems,
the lack of basic healthcare facilities, the low
population awareness of the disease and its
complications and the inadequate access to
screening and diagnostic procedures.6 This
inadequate access to proper healthcare
explains the increased vulnerability of chil-
dren affected with SCD to exacerbations and
complications with resulting major psycho-
logical and socioeconomic consequences for
them and their families.6 8
Vaso-occlusive crises and haemolysis are
the clinical hallmarks of SCD.2 The polymer-
isation of deoxy-haemoglobin S leads to the
formation of non-ﬂexible sickle-shaped red
blood cells that occlude terminal vessels.2
Repeated vaso-occlusive crises in various
organs could result in a wide range of com-
plications classiﬁed as locomotor (chronic
pain, aseptic osteonecrosis), renal (renal
Mengnjo MK, et al. BMJ Open 2016;6:e012981. doi:10.1136/bmjopen-2016-012981 1
Open Access Protocol
group.bmj.com on October 20, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
infarction with papillary necrosis, medullary ﬁbrosis
with focal segmental glomerulosclerosis, glomerular
hyperﬁltration and tubular dysfunction), neurological
(ischaemic or haemorrhagic strokes, silent brain infarcts)
and cardiorespiratory (acute chest syndrome).12–14
Regarding haemolysis, it refers to the continuous destruc-
tion of sickled red blood cells within the blood vessels or
the spleen (following splenic sequestration). This could
result in chronic anaemia, aplastic crises and eventually
heart failure in some cases. Patients with SCD are also sus-
ceptible to severe and often multifocal infections as a
result of several factors, including functional asplenia,
micronutrient deﬁciencies and tissue ischaemia.14 15
Neurological manifestations of SCD are common and
include chronic headache, epilepsy, ischaemic or haemor-
rhagic stroke, cognitive impairment due to chronic
anaemia, hypoxia and silent infarcts.12–14
So far, most studies have focused on cerebrovascular
complications that are the most debilitating and need
urgent implementation of prevention and management
strategies. However, the majority of these studies have
involved patients from outside the African continent
which currently has the highest burden of disease. In
the African context, the relative proportion of vascular
and non-vascular neurological complications might be
different. Most studies in Africa have included small
samples and putting their ﬁndings together in a system-
atic review might help to better estimate the prevalence
of the various neurological complications of SCD, thus
providing useful data for policymakers.
Objective
The objective of this study is to summarise the epidemio-
logical data available on the prevalence of neurological
complications in patients with SCD in Africa.
METHODS
This review protocol has been prepared according to
the 2015 Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols (PRISMA-P) guide-
lines.16 It has been registered in the PROSPERO
International Prospective Register of Systematic Reviews
(http://www.crd.york.ac.uk/PROSPERO), registration
number CRD42014015376.
Criteria for considering studies for the review
Inclusion criteria
All observational studies and clinical trials conducted in
Africa from 1 January 1950 to 31 May 2016, and report-
ing epidemiological data on the neurological complica-
tions of SCD will be included without any restriction of
language.
Exclusion criteria
1. Studies conducted outside of Africa.
2. Case series with small sample size (<30 participants),
letters, reviews, commentaries and editorials.
3. Duplicates; for studies published in more than one
report, the most comprehensive and up-to-date
version will be used.
4. Studies whose full data will not be accessible even
after request from the authors.
Search strategy for the identification of relevant studies
The search strategy will be implemented in two steps.
Search in bibliographic databases
We will search PubMed MEDLINE, EMBASE, and the
African Index Medicus from 1 January 1950 to 31 May
2016, for observational studies and clinical trials report-
ing data on the neurological complications of SCD in
Africa. As summarised in table 1, the search strategy will
be built by combining relevant terms related to SCD
and its possible neurological complications with the
names of the 54 African countries.
Forwards and backwards citation searching
Forwards and backwards citation searching will be per-
formed to identify additional sources of data that were
missed during the search in bibliographic databases.
Selection of studies for inclusion in the review
Two investigators (NN and MKM) will independently
perform the literature search. Titles and abstracts will be
screened and the full texts of all relevant articles will be
retrieved. These full texts will be screened using a pre-
tested standardised form to include eligible studies.
Disagreements will be resolved by consensus, with con-
sultation of a third author ( JKT). Authors of publica-
tions reporting unclear data that may be subject to
multiple interpretations will be contacted by email for
clariﬁcation or to request supplemental information. If a
study is excluded, the reasons will be documented. The
PRISMA ﬂow chart16 will be used to summarise the
entire selection process (ﬁgure 1).
Assessment of the methodological quality and risk of bias
The Risk of Bias Tool for Prevalence Studies established
by Hoy et al17 (table 2) and the Cochrane guidelines
available in Review Manager V.5.3 (http://tech.
cochrane.org/revman) will be used to evaluate the
methodological quality and risk of bias for each study.
The STROBE checklist18 will be used to evaluate the
quality of reporting in each paper.
Data extraction
A data extraction sheet will be used to collect information
about the country, the year of publication, the language
of publication, the type of publication, the study design,
the number of participants, the mean age of the popula-
tion, the diagnostic criteria for SCD and the prevalence
of the various neurological complications of SCD. Where
prevalence rates or information for calculating them
(eg, sample size, frequency of outcomes) are lacking, we
will contact the corresponding author to request the
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Table 1 Search strategy for MEDLINE and adaptability to regional databases
Search Search terms
1 Sickle cell disease OR sickle cell anemia OR sickle cell hemoglobinopathy OR drepanocytosis
2 Headache OR seizure OR epilepsy OR cognitive deficit OR intellectual disability OR intellectual impairment OR
cognitive impairment OR neuropsychologic* deficit OR cerebral infarct OR white matter lesions OR subcortical
infarct OR cortical infarct OR stroke OR ischemic stroke OR hemorrhagic stroke OR ischaemic stroke OR
haemorrhagic stroke OR intraventricular hemorrhage OR aneurysm OR parenchymal hemorrhage OR fat embolism
OR subarachnoid hemorrhage OR arterial stenosis OR intracranial stenosis OR carotid stenosis OR moya moya OR
moya* OR epidural hematoma OR borderline infarct OR watershed infarct OR fat embolism OR cerebral venous
thrombosis OR hemiparesis OR hemiplegia OR quadriparesis OR quadriplegia OR monoparesis OR cranial nerve
palsy OR cerebral vasoconstriction OR leukoencephalopathy OR encephalopathy OR encephalitis OR meningitis
OR brain* OR spine OR spinal cord OR neurologic* complications OR central nervous system OR peripheral
nervous system OR neuropathy OR polyneuropathy OR cortical atrophy OR brain atrophy OR posterior reversible
encephalopathy syndrome
3 Africa* OR Algeria OR Angola OR Benin OR Botswana OR “Burkina Faso” OR Burundi OR Cameroon OR “Canary
Islands” OR “Cape Verde” OR “Central African Republic” OR Chad OR Comoros OR Congo OR “Democratic
Republic of Congo” OR Djibouti OR Egypt OR “Equatorial Guinea” OR Eritrea OR Ethiopia OR Gabon OR Gambia
OR Ghana OR Guinea OR “Guinea Bissau” OR “Ivory Coast” OR “Cote d’Ivoire” OR Jamahiriya OR Kenya OR
Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mayotte OR
Morocco OR Mozambique OR Namibia OR Niger OR Nigeria OR Principe OR Reunion OR Rwanda OR “Sao
Tome” OR Senegal OR Seychelles OR “Sierra Leone” OR Somalia OR “South Africa” OR “St Helena” OR Sudan
OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR “Western Sahara” OR Zaire OR Zambia OR
Zimbabwe OR “Central Africa” OR “Central African” OR “West Africa” OR “West African” OR “Western Africa” OR
“Western African” OR “East Africa” OR “East African” OR “Eastern Africa” OR “Eastern African” OR “North Africa”
OR “North African” OR “Northern Africa” OR “Northern African” OR “South African” OR “Southern Africa” OR
“Southern African” OR “sub Saharan Africa” OR “sub Saharan African” OR “subSaharan Africa” OR “subSaharan
African)” NOT (“guinea pig” OR “guinea pigs” OR “aspergillus niger)”
4 # 1 AND # 2 AND # 3
5 #4 Limits: 1986/01/01 to 2016/05/31
Figure 1 PRISMA flow diagram.
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information. In case of multinational studies, we will
separate the results to show the prevalence of the
SCD-related neurological complications in each country.
In the event that it is not possible to disaggregate the data
by country, the study will be presented as one and the
countries in which the study was carried out will be shown.
Statistical analysis
Heterogeneity will be evaluated by the χ2 test on
Cochrane’s Q statistic19 and quantiﬁed by calculating the
I2.20 I2 values of 25%, 50% and 75% will be considered as
representing low, medium and high heterogeneity, respect-
ively. Assessment of publication bias and selective reporting
will be done by examining articles’ abstracts and by using
funnel plots and the Egger’s test.21 If there is no substantial
heterogeneity across studies, we will conduct a global
meta-analysis. For this purpose, the study-speciﬁc estimates
will be determined from the point estimate and the appro-
priate denominators, assuming a binominal (or Poisson for
incidence data) distribution. We will pool the study-speciﬁc
estimates using a random-effects meta-analysis model after
stabilising the variance of individual studies with the
Freeman-Tukey double arcsine transformation.22 Where
substantial heterogeneity is detected, we will perform sub-
group analyses to explore the possible sources of hetero-
geneity using the following grouping variables: age (below
vs at or above the median), gender (gender-speciﬁc
analysis where possible; and below vs at or above the
median proportion of men across study), study setting
(rural vs urban; hospital vs community-based), geograph-
ical region (central, eastern, northern, southern and
western Africa), time when the study was conducted/pub-
lished (below vs at or above the median) and study quality.
If the data are limited or cannot be pooled due to substan-
tial heterogeneity, the ﬁndings will be presented in a narra-
tive form.
We will assess inter-rater agreement for study inclusion
using Cohen’s κ coefﬁcient.23 Data will be analysed
using the statistical software R (V.3.0.3 (2014-03-04), The
R Foundation for statistical computing, Vienna, Austria).
Reporting of this review
The proposed systematic review will be reported follow-
ing the PRISMA guidelines.23 A PRISMA checklist will
be published with the ﬁnal report.
Potential amendments
We do not intend to make any amendment to this proto-
col. However, any necessary amendment will be docu-
mented and reported transparently.
Ethics and dissemination
The current study will be based on published data. An
ethical clearance is therefore not required. The ﬁnal
Table 2 Risk of bias assessment tool
Risk of bias item
Response: yes (low risk)
or no (high risk)
External validity
Was the study target population a close representation of the national population in
relation to relevant variables?
Was the sampling frame a true or close representation of the target population?
Was some form of random selection used to select the sample, OR, was a census
undertaken?
Was the likelihood of non-participation bias minimal?
Internal Validity
Were data collected directly from the participants (as opposed to medical records)?
Were acceptable case definitions of sickle cell disease and the assessed neurologic
complications used?
Were reliable and accepted diagnostic methods for sickle cell disease and the
assessed neurologic complications utilized?
Was the same mode of data collection used for all participants?
Was the length of the shortest prevalence period for the parameter of interest
appropriate?
Were the numerator(s) and denominator(s) for the calculation of the assessed
neurologic complications appropriate?
Summary item on the overall risk of study bias
Low Risk of Bias: 8 or more ‘yes’ answers.
Further research is very unlikely to change our confidence in the estimate.
Moderate Risk of Bias: 6 to 7 ‘yes’ answers.
Further research is likely to have an important impact on our confidence in the estimate
and may change the estimate.
High Risk of Bias: 5 or fewer ‘yes’ answers.
Further research is very likely to have an important impact on our confidence in the
estimate and is likely to change the estimate.
The Risk of Bias Tool for Prevalence Studies developed and modified by Hoy et al.17
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report of the systematic review will be published as an
original article in a peer-reviewed journal. Findings will
be presented at conferences and submitted to relevant
health authorities. We also plan to perform regular
updates of the review every 5 years.
CONCLUSION
Neurological complications of SCD may be more fre-
quent in Africa than currently reported. The rarity of
prevalence studies of these complications makes it difﬁ-
cult to manage them. The most commonly reported
neurological complication of SCD is overt stroke.
However, the frequency of silent infarcts, intracranial
bleeding, leukoencephalopathy, cerebral atrophy and
impaired cognition is most often underestimated since
these are usually revealed by neuropsychological and
neuroimaging screening studies in otherwise asympto-
matic patients with SCD. The high prevalence of these
ﬁndings in young patients with SCD underscores the fact
that central nervous system injuries begin early in life.
The strength of this review is that it will be the ﬁrst to
quantify the magnitude of neurological complications of
SCD across Africa where this haematological condition is
highly prevalent. Furthermore, this review might identify
speciﬁc research challenges to be addressed in future
studies of neurological complications of SCD in Africa.
The main possible limitations of this review could be
the scarcity of studies on the subject and the predomi-
nance of poor quality studies (due to lack of population
awareness and inadequate screening or follow-up) that
might result in an underestimation of the real preva-
lence of the neurological complications of SCD in
Africa. Regional differences in the standard of care
could also lead to signiﬁcant heterogeneity among
studies, thus precluding the meta-analysis and making it
difﬁcult to get a global picture of the burden of neuro-
logical complications of SCD across Africa.
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